Prescription medicine
Crisaborole Brand names: Eucrisa
Crisaborole (Eucrisa) is a prescription medicine with an FDA approval on record since 2016. No generic is listed; pharmacies paid $11.68 per gram (Eucrisa 2% ointment) in the October 7, 2026 NADAC survey.
- No generic listed
Check it at the source: the crisaborole FDA label on DailyMed (effective September 23, 2025, Pfizer Laboratories Div Pfizer Inc); the NDA 207695 record on Drugs@FDA; every crisaborole label on DailyMed.
Highlights of the record
FDA label of September 23, 2025; NDC Directory, Drugs@FDA and Orange Book, October 8, 2026; NADAC October 7, 2026
Used for
From the label: indications and usageEUCRISA is indicated for topical treatment of mild to moderate atopic dermatitis in adult and pediatric patients 3 months of age and older.
Forms and strengths
- 20 mg/g
Ointment.
On the market
- Earliest approval on file
- December 14, 2016 Eucrisa, Anacor Pharms Inc; Drugs@FDA’s file, where older or withdrawn approvals can be missing
- Generic approvals
- 1 first September 24, 2026; 1 with a marketed status in Drugs@FDA
- Labelers listed (NDC)
- 1 of which 0 under generic applications, 1 under brand applications, repackagers included
- Last listed patent
- July 20, 2030 Eucrisa ointment; not a generic launch date
Supply and safety
- Pharmacy cost (NADAC)
- $11.68 per gram Eucrisa 2% ointment
- Shortage (FDA)
- No current entry
- Recalls by its makers (FDA)
- No recall recorded
- FAERS reports
- 9,540 through July 30, 2026
What is crisaborole used for?
From the label: indications and usageEUCRISA is indicated for topical treatment of mild to moderate atopic dermatitis in adult and pediatric patients 3 months of age and older. EUCRISA is a phosphodiesterase 4 inhibitor indicated for topical treatment of mild to moderate atopic dermatitis in adult and pediatric patients 3 months of age and older.
Conditions named in the indications of crisaborole's FDA labels, with every medicine labeled for each:
FDA pharmacologic class: Phosphodiesterase 4 Inhibitor.
Source: FDA drug label (Eucrisa), NDA207695 (Anacor Pharms Inc), as published by Pfizer Laboratories Div Pfizer Inc, effective September 23, 2025 (SPL set 609b77de-1ca3-4783-b8f5-01a9c0f1d77d), via openFDA; the full label on DailyMed
Is there a generic for crisaborole (Eucrisa)?
The FDA approved the first generic crisaborole on September 24, 2026. 1 generic application is approved; 1 of it carries a current (not discontinued) marketing status in Drugs@FDA; that status is not evidence that the generic is on sale.
The Orange Book lists 4 patents for Eucrisa ointment: the compound patent runs to June 29, 2029 (pediatric exclusivity to December 29, 2029), and the last listed entry to July 20, 2030. A patent or exclusivity date is not the date a generic goes on sale: court cases and settlements move it either way.
- 2016 earliest approval on file
- 2026 first generic approved
- 2030 last listed patent
Source: Drugs@FDA, FDA NDC Directory and the Orange Book (openFDA bulk files, October 8, 2026)
What do pharmacies pay for crisaborole (Eucrisa)?
In CMS's NADAC survey of October 7, 2026, pharmacies paid $11.68 per gram (Eucrisa 2% ointment), about the same as a year earlier. The chart's scale runs from the lowest to the highest price shown, not from zero. NADAC is what retail pharmacies paid their wholesalers, per unit, in CMS's monthly survey; what a patient pays depends on insurance and the pharmacy.
- Eucrisa 2% ointment (brand)
| Strength and form | Brand or generic | Pharmacy cost | 30 tablets, or one pen or vial | 12-month change |
|---|---|---|---|---|
| Eucrisa 2% ointment | Brand | $11.68 per gram | n/a | no change |
Source: CMS National Average Drug Acquisition Cost (NADAC) survey, October 7, 2026: what retail pharmacies paid per unit; not a counter price
What do FAERS reports show for crisaborole?
The FDA Adverse Event Reporting System holds 9,540 reports that list crisaborole among the medicines taken, through July 30, 2026, each a report of something that happened, not proof the medicine caused it; 25 are coded as a death and 155 as a hospital stay. Counts follow how widely a medicine is used and watched, and they are not a measure of how risky it is. Reports rose sharply in 2018 (2,074, against a median of 676 a year): FAERS counts follow reporting, which news, litigation and label changes can drive, not how often a reaction happens.
Reports received each year
The most reported reactions
Source: FDA Adverse Event Reporting System (FAERS) via openFDA, reports through July 30, 2026
What else is labeled for the same conditions as crisaborole?
7 other medicines are given the same way (topical) and in the same FDA class as crisaborole or labeled mainly for the same use (eczema (atopic dermatitis)), the same class first. Eczema (atopic dermatitis) lists all 26 medicines labeled for it, by any route. They are listed as records, not as substitutes: whether one can replace another is a prescriber's decision.
| Medicine | Shared indication | Generic labelers (topical) | Pharmacy cost | Shortage |
|---|---|---|---|---|
| Roflumilast | Eczema (atopic dermatitis) | none listed | $15.38 per gram 0.3% foam | No current entry |
| Difamilast | Eczema (atopic dermatitis) | none listed | n/a | No current entry |
| Oatmeal | Eczema (atopic dermatitis) | none listed | n/a | No current entry |
| Desonide | Eczema (atopic dermatitis) | 12 labelers | $0.252 per gram 0.05% cream | No current entry |
| Pimecrolimus | Eczema (atopic dermatitis) | 2 labelers | $3.31 per gram 1% cream | No current entry |
| Delgocitinib | Eczema (atopic dermatitis) | none listed | n/a | No current entry |
| Ruxolitinib | Eczema (atopic dermatitis) | none listed | $34.01 per gram 1.5% cream | No current entry |
Every medicine labeled for the same conditions as crisaborole
Source: FDA drug labels (indications), NDC Directory, NADAC of October 7, 2026, FDA shortages (October 8, 2026)
What next?
- Alternatives to crisaborole
- 7 medicines for the same use
- Other phosphodiesterase 4 inhibitors
- the pharmacologic class, with prices and generics
- Crisaborole side effects
- the label's list beside FAERS reports
- Check an interaction
- what two or more labels say about each other